Literature DB >> 36157093

Contemporary Treatment of Pulmonary Embolism: Medical Treatment and Management.

Stephen Moreland1, Debabrata Mukherjee1, Nils P Nickel1.   

Abstract

Pulmonary embolus (PE) is defined as obstruction of the pulmonary artery or one of its branches by material (e.g., thrombus, tumor, air, or fat) but most commonly due to thrombus originating from the lower extremity deep veins. We reviewed the current literature describing the optimal medical treatment and management of PE. Databases (PubMed, the Cochrane Library, Embase, EBSCO, Web of Science, and CINAHL) were searched for relevant studies and guidelines for management of patients with PE. The initial approach to patients with suspected PE should focus upon stabilizing the patient while further workup for risk stratification is in progress. In most cases, anticoagulation should ideally be started even prior to confirming PE, if risk-benefit regarding suspicion of PE and bleeding risk is favorable. Once the diagnosis is confirmed, risk stratification will guide further therapies consisting of anticoagulation, thrombolysis, or catheter-directed interventions. Data for initial, long-term, and indefinite anticoagulation, and factors that determine whether or not a patient can be treated in the outpatient setting, are reviewed and discussed. International College of Angiology. This article is published by Thieme.

Entities:  

Keywords:  anticoagulation; pharmacotherapy; pulmonary embolism; risk stratification; thrombolytic

Year:  2022        PMID: 36157093      PMCID: PMC9507607          DOI: 10.1055/s-0042-1750329

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  56 in total

1.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

Review 2.  Role of the anticoagulant monitoring service in 2018: beyond warfarin.

Authors:  Nathan P Clark
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators.

Authors: 
Journal:  Chest       Date:  1990-03       Impact factor: 9.410

4.  Pulmonary Embolism Response Teams: Pursuing Excellence in the Care for Venous Thromboembolism.

Authors:  Mateo Porres-Aguilar; Javier E Anaya-Ayala; David Jiménez; Debabrata Mukherjee
Journal:  Arch Med Res       Date:  2019-10-05       Impact factor: 2.235

5.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

6.  Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.

Authors:  S Z Goldhaber; G Agnelli; M N Levine
Journal:  Chest       Date:  1994-09       Impact factor: 9.410

7.  Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia.

Authors:  Kyle A Davis; Daphne O Davis
Journal:  Eur J Haematol       Date:  2017-07-25       Impact factor: 2.997

8.  Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data.

Authors:  Ghadeer K Dawwas; Charles E Leonard; James D Lewis; Adam Cuker
Journal:  Ann Intern Med       Date:  2021-12-07       Impact factor: 25.391

Review 9.  Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines.

Authors:  Zhenguo Zhai; Chenghong Li; Yaolong Chen; Grigorios Gerotziafas; Zhenlu Zhang; Jun Wan; Peng Liu; Ismaïl Elalamy; Chen Wang
Journal:  Thromb Haemost       Date:  2020-04-21       Impact factor: 5.249

10.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Authors:  Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.